

MSK and Pediatric Cancer Facts

Pediatric cancer research is underfunded. Only 4% of the National Cancer Institute's research budget is dedicated to pediatric cancers, making the donations from Kids Walk important to doctors and researchers at Memorial Sloan Kettering Cancer Center (MSK).

Kids Walk participants, donors, and supporters of all ages are making a difference by raising money for lifesaving pediatric cancer research. Every dollar raised gives the doctors and researchers at MSK Pediatrics what they need to discover new and better treatment options for children around the world. Together, we can make progress possible.

FACTS ABOUT PEDIATRIC CANCERS

- Childhood cancers are the leading cause of death by disease in children under the age of 15 in the U.S.
- Only 4% of federal funding for cancer research goes to pediatric cancers.
- Pediatric cancers are classified as a rare form of cancer.
- Because of advances in pediatric cancer research, more than 80% of childhood cancer patients in the U.S. now become long-term survivors.

FACTS ABOUT MSK PEDIATRICS

- Treats more children with cancer than any other hospital in the U.S.
- Has the largest pediatric oncology program in the U.S.
- Is home to a new Pediatric Precision Medicine Program — an initiative that promises to deliver targeted therapies to more children battling cancer than ever before.
- Conducts over 100 clinical trials that provide new and better treatment options for children.
- Sends 90% of the children receiving chemotherapy and other treatments home at the end of the day, so they can spend more time with their families.
- Employs full-time school teachers, so children with pediatric cancers stay on track in school.

Kids Walk is proud to be part of MSK and is committed to funding pediatric cancer research at MSK. Founded in 1884, MSK is the world's oldest and largest private cancer center devoted to extraordinary patient care, cutting-edge research, and transformative educational programs. For more than a century, MSK has been at the forefront of the most significant advances in the treatment of pediatric cancers — even the rarest types. One of its greatest strengths is the close collaboration between the doctors and researchers. Working together, they can provide patients with the best care available and move discoveries swiftly to patients' bedsides without missing a beat.